Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vorasidenib in Asian Participants With Residual or Recurrent Grade 2 IDH-Mutant Glioma
NCT06780930Phase 3Active, not recruiting
- Sponsor
- Servier
- Start
- Oct 2024
- Primary completion
- May 2026
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 3 trial of vorasidenib in glioma, sponsored by Servier. Started Oct 2024; status: active, not recruiting.
02
Drugs
vorasidenib
03
Conditions
glioma
Beyond the preview
Go deeper on NCT06780930.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06780930.